Blarcamesine
As of the edition of 20 October 2026, Blarcamesine is a small molecule: in active development; acts on SIGMAR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2019
- Kind
- Small molecule
- Registered trials
- 9, 0 stopped early
- Disease areas
- Nervous system; Mental health; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Q99720 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 4 | 4 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Anavex Life Sciences | Lead sponsor of trials | 2014 to now |